Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429225 | 1.00 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16429269 | 0.95 | SIGMAR1 (0.45) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16429220 | 0.94 | SIGMAR1 (0.45) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16429108 | 0.89 | CHRNB2 (0.39) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16428820 | 0.87 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16428822 | 0.87 | SIGMAR1 (0.48) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16428818 | 0.85 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16429323 | 0.85 | MAOA (0.42) | SIGMAR1MEN1KMT2A | |
| SCHEMBL16428941 | 0.84 | SIGMAR1 (0.43) | SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16247175 | 0.83 | SIGMAR1 (0.42) | SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10440955-B2 | Methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2018-05-10 | — | — | US | disclosed |
| US-9839219-B2 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | CURZA GLOBAL, LLC | 2016-11-17 | — | — | US | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMS, SMOX | SIGMAR1 1551/4885CHRNB2 4820/4885CHRNB4 4831/4885 |
| US-10440955-B2 | Methods comprising a biocidal polyamine | SRM, SMOX, SMS | SIGMAR1 1642/4885CHRNB2 4798/4885CHRNB4 4816/4885 |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | SIGMAR1 1771/4885CHRNB2 4818/4885CHRNB4 4839/4885 |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | SIGMAR1 1771/4885CHRNB2 4818/4885CHRNB4 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.